ACCUMULATION OF PLATINUM IN THE INTERVERTEBRAL DISKS AND VERTEBRAE OF OVARIAN TUMOR-BEARING PATIENTS TREATED WITH CISPLATIN

被引:14
作者
MINAMI, T
HASHII, K
TATEYAMA, I
KADOTA, E
TOHNO, Y
TOHNO, S
UTSUMI, M
YAMADA, MO
ICHII, M
NAMIKAWA, K
OKAZAKI, Y
机构
[1] KISHIWADA MUNICIPAL HOSP,DIV GYNECOL,OSAKA,JAPAN
[2] KISHIWADA MUNICIPAL HOSP,DIV PATHOL,OSAKA,JAPAN
[3] NARA MED UNIV,DEPT ANAT,KASHIHARA,NARA,JAPAN
关键词
CISPLATIN; PLATINUM; INTERVERTEBRAL DISC; VERTEBRA; OVARIAN TUMOR THERAPY; ICP-MS;
D O I
10.1007/BF02911522
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Platinum was determined by the inductively coupled plasma mass spectrometry (ICP-MS) in the intervertebral discs and vertebrae of ovarian tumor bearing patients treated with cis-diamminedichloro-platinum (II) (cisplatin). Platinum was 0.05 ng/mL at the absolute detection limit, and platinum was undetectable in the intervertebral discs and vertebrae of human specimens without cisplatin treatments. On the other hand, platinum was detected in the intervertebral discs and vertebrae of patients administered cisplatin, and platinum concentration was at levels of 1.06-10.31 mu g/g dry tissue in the intervertebral discs and 0.60-1.28 mu g/g dry tissue in the vertebrae, respectively. The platinum level of intervertebral discs was 4.3-fold higher than that of the vertebrae. Thus, platinum accumulates greatly in the intervertebral discs and somewhat in the vertebrae after administering cisplatin to patients for therapy.
引用
收藏
页码:253 / 257
页数:5
相关论文
共 21 条
[1]   DETERMINATION OF PLATINUM IN URINE, ULTRAFILTRATE, AND WHOLE PLASMA BY ISOTOPE-DILUTION GAS-CHROMATOGRAPHY MASS-SPECTROMETRY COMPARED TO ELECTROTHERMAL ATOMIC-ABSORPTION SPECTROMETRY [J].
AGGARWAL, SK ;
GEMMA, NW ;
KINTER, M ;
NICHOLSON, J ;
SHIPE, JR ;
HEROLD, DA .
ANALYTICAL BIOCHEMISTRY, 1993, 210 (01) :113-118
[2]   DETERMINATION OF HUMAN-BODY BURDEN BASELINE DATA OF PLATINUM THROUGH AUTOPSY TISSUE ANALYSIS [J].
DUFFIELD, FVP ;
YOAKUM, A ;
BUMGARNER, J ;
MORAN, J .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1976, 15 (JUN) :131-134
[3]  
FEUN LG, 1984, CANCER, V54, P794, DOI 10.1002/1097-0142(19840901)54:5<794::AID-CNCR2820540503>3.0.CO
[4]  
2-F
[5]  
GINOS JZ, 1987, J NUCL MED, V28, P1844
[6]   CISPLATIN NEUROTOXICITY - THE RELATIONSHIP BETWEEN DOSAGE, TIME, AND PLATINUM CONCENTRATION IN NEUROLOGIC TISSUES, AND MORPHOLOGICAL EVIDENCE OF TOXICITY [J].
GREGG, RW ;
MOLEPO, JM ;
MONPETIT, VJA ;
MIKAEL, NZ ;
REDMOND, D ;
GADIA, M ;
STEWART, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (05) :795-803
[7]  
HAMERS FPT, 1993, CANCER RES, V53, P544
[8]  
HILL JM, 1975, CANCER CHEMOTH REP 1, V59, P647
[9]  
Irie T, 1983, IYAKUHIN KENKYU, V14, P384
[10]  
JONES TW, 1985, LAB INVEST, V52, P363